TherapeuticsMD Inc. (TXMD) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, TXMD scores 34 out of 100, earning a grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The score is the sum of five pillars, each weighted out of 20:

• Fundamental Cash Engine: 7 / 20. The rating cites ROIC of -12.9% and an FCF yield of 0%. For a prospective investor, this means the business is not currently generating a return on invested capital or free cash flow that would support the share price on cash-based valuation.
• Whale 13F Flow: 4 / 20. This pillar reflects institutional accumulation and options positioning. A low score indicates weak institutional support in the source data.
• Insider Conviction: 5 / 20. This pillar draws on SEC Form 4 and Congressional PTR cluster flow. The low score signals limited evidence of insider or cluster conviction.
• Macro Regime Fit: 8 / 20. The rating shows a beta of 1.0 and a sector sensitivity profile. This pillar offers little differentiation; the stock's market sensitivity is neutral, but the score reflects weak fit with the prevailing regime per the rating's methodology.
• Forensic Balance Sheet: 10 / 20. The rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. The Piotroski reading is weak, and the Altman figure is the strongest forensic datapoint in the set.

Investor implications: the upside case rests on any future improvement in operating performance that could lift ROIC and cash generation from negative territory; the valuation tradeoff is that with no positive earnings or free cash flow in the source data, the stock trades on factors outside the reported cash engine. The lowest-scoring pillars (Insider Conviction and Whale 13F Flow) suggest the market's most informed participants are not signaling conviction. The balance sheet pillar is middling rather than distressed, which means solvency is a less immediate concern than profitability.

Per the SEC financials, revenue declined from $1.8M in FY 2024 to $0.0M in FY 2025, and operating losses narrowed from $-6.1M to $-4.4M over the same span. Gross, operating, and net margins are each reported as 0% in the market data. ROIC is -12.9%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with a Debt/Equity ratio of 0.5. These figures describe a company reporting no revenue in its latest fiscal year and continuing operating losses.

Per the recent news and catalysts feed, five TXMD items appear. Two are tagged CATALYST (MarketWatch reports describing a strong trading day, both green), and three are tagged MARKET WIRE with yellow signals (a Barron's chart piece and two MarketWatch reports describing underperformance on Monday and Tuesday). No specific product, regulatory, or financing catalyst is described in the item summaries; they are market-action reports. Risk watch items: the recurring underperformance headlines and the absence of named fundamental catalysts. Per the Butterfly Supply-Chain Graph, no proprietary signals are present.

• What specific products or pipeline assets generate the company's revenue, and what drove the drop from $1.8M to $0.0M in FY 2025?
• What are the cash, debt, EPS, and free cash flow figures for each reported period, which are currently N/A in the financial data?
• What is the company's cash runway given a $21.2M market capitalization and continuing operating losses?
• Are there any named regulatory, clinical, or financing catalysts behind the recent trading-day headlines?
• What institutional, insider, or analyst positioning exists, given that the holders and analyst data sections are empty?